Commentary
Commentary
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
Commentary
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Commentary
Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk. Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and ...
Commentary
Democrats Can’t End Private-Sector Drug Innovation Fast Enough
In November, a group of Democrats in the U.S. House made clear that they’ll sacrifice medical innovation for lower drug prices if they ever reclaim Congress. Patients today and tomorrow will be the losers in that trade. Read the op-ed here.
Commentary
The real story behind Trump’s GLP-1 price cut: Markets still rule
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx. Lilly and ...
Commentary
Why reforming PBMs is the key to lowering drug costs
If lawmakers want to make pharmaceuticals more affordable, they should look past populist policies like price controls that will only make matters worse and set their sights on reforming the Pharmacy Benefit Manager market. PBMs manage the drug benefits for insurers and negotiate discounts with drug manufacturers. You probably use ...
Business & Economics
San Francisco wants to control what you eat
Food choices? Those are for the government to decide. That’s the message behind a lawsuit filed by San Francisco City Attorney David Chiu against “some of the country’s largest manufacturers of ultra-processed foods.” It is the first government lawsuit in the nation against food companies. Chiu’s office claims “the proliferation ...
Commentary
GAO Provides Yet More Evidence for Why Enhanced Obamacare Subsidies Must Expire
Defrauding the government through Obamacare’s insurance exchanges is shockingly easy, per a new government report. The study found that federal insurance subsidies were granted for 90 percent of the fake exchange accounts set up as part of a Government Accountability Office investigation — at a cost of more than $10,000 ...
Commentary
Despite Dems’ protests, affordable health plans are about to multiply
Obamacare premiums are climbing yet again during open enrollment. But there’s also some good news for cost-conscious shoppers ― a new way to secure affordable coverage without forgoing access to care. This year, many people can buy low-cost “catastrophic” health plans for the very first time. Combine one of these ...
Commentary
How Competition Drives Healthcare Innovation & Affordability
Making healthcare more affordable requires reforms that strengthen competitive markets, as I outlined in a recent Pacific Research Institute1 paper. Unfortunately, as we’re seeing in California and elsewhere, the trend in government is away from competition and toward fewer choices, hurting patients and increasing costs. When applied to other industries, ...
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
What America Needs from a GOP Healthcare Package
The U.S. House just passed legislation that will help make health insurance more affordable — without extending the enhanced premium subsidies for exchange coverage that Democrats enacted during the COVID-19 pandemic. The House action comes on the heels of votes on two measures in the Senate: one from Democrats that ...
Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk. Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and ...
Democrats Can’t End Private-Sector Drug Innovation Fast Enough
In November, a group of Democrats in the U.S. House made clear that they’ll sacrifice medical innovation for lower drug prices if they ever reclaim Congress. Patients today and tomorrow will be the losers in that trade. Read the op-ed here.
The real story behind Trump’s GLP-1 price cut: Markets still rule
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx. Lilly and ...
Why reforming PBMs is the key to lowering drug costs
If lawmakers want to make pharmaceuticals more affordable, they should look past populist policies like price controls that will only make matters worse and set their sights on reforming the Pharmacy Benefit Manager market. PBMs manage the drug benefits for insurers and negotiate discounts with drug manufacturers. You probably use ...
San Francisco wants to control what you eat
Food choices? Those are for the government to decide. That’s the message behind a lawsuit filed by San Francisco City Attorney David Chiu against “some of the country’s largest manufacturers of ultra-processed foods.” It is the first government lawsuit in the nation against food companies. Chiu’s office claims “the proliferation ...
GAO Provides Yet More Evidence for Why Enhanced Obamacare Subsidies Must Expire
Defrauding the government through Obamacare’s insurance exchanges is shockingly easy, per a new government report. The study found that federal insurance subsidies were granted for 90 percent of the fake exchange accounts set up as part of a Government Accountability Office investigation — at a cost of more than $10,000 ...
Despite Dems’ protests, affordable health plans are about to multiply
Obamacare premiums are climbing yet again during open enrollment. But there’s also some good news for cost-conscious shoppers ― a new way to secure affordable coverage without forgoing access to care. This year, many people can buy low-cost “catastrophic” health plans for the very first time. Combine one of these ...
How Competition Drives Healthcare Innovation & Affordability
Making healthcare more affordable requires reforms that strengthen competitive markets, as I outlined in a recent Pacific Research Institute1 paper. Unfortunately, as we’re seeing in California and elsewhere, the trend in government is away from competition and toward fewer choices, hurting patients and increasing costs. When applied to other industries, ...
